MEDI 6012

Drug Profile

MEDI 6012

Alternative Names: ACP-501; MEDI-6012; recombinant-lecithin-cholesterol-acyltransferase; rhLCAT

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AlphaCore Pharma
  • Developer AstraZeneca; MedImmune
  • Class Acyltransferases; Antianaemics; Antihyperlipidaemics; Cardiovascular therapies; Enzymes; Recombinant proteins
  • Mechanism of Action Apolipoprotein A I stimulants; Cholesterol modulators; Transferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lecithin acyltransferase deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute coronary syndromes; Atherosclerosis; Coronary artery disease
  • Phase I Arterial thrombosis
  • Preclinical Adrenal gland disorders; Anaemia; Lecithin acyltransferase deficiency; Sickle cell anaemia

Most Recent Events

  • 11 Nov 2017 Adverse events and pharmacodynamics data from a phase IIa trial in Coronary artery disease presented at 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 11 Nov 2017 Pharmacodynamics data from a clinical trial in Coronary artery disease presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 02 Nov 2017 MedImmune completes a phase IIa trial for Atherosclerosis (In the elderly) in USA (IV) (NCT03004638)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top